GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
February 20 2020 - 4:29AM
Dow Jones News
By Carlo Martuscelli
Clinical-stage biotechnology business Immatics said Thursday
that GlaxoSmithKline will license two of its T-cell therapy
candidates being developed to treat cancer for a $50 million
upfront payment.
Under the terms of the agreement, Glaxo will be responsible for
developing, manufacturing and commercializing the investigative
treatments. Immatics said that, in addition to the award upfront,
is eligible for over $550 million in development, regulatory and
commercial payments for each product, plus royalties.
The collaboration deal also includes the option for the British
pharmaceutical company to license additional candidates. German
biotech startup Immatics said that it is developing treatments that
uses natural or engineered T-cells, a kind of immune cell, to fight
solid tumors.
This latest deal brings Glaxo's cell-therapy pipeline up to six
assets, from four previously. In Europe there are currently two
approved cell-therapy products, both to treat certain blood
cancers, developed by drug makers Gilead Science and Novartis.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com;
@carlomartu
(END) Dow Jones Newswires
February 20, 2020 05:14 ET (10:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024